Transmembrane Activator and CAML Interactor (TACI): Another Potential Target for Immunotherapy of Multiple Myeloma?

Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma

(2020) Lorena Perez-Amill et al.   HAEMATOLOGICA

Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

(2020) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches

(2020) Nina Shah et al.   LEUKEMIA

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

(2020) Gils Roex et al.   Pharmaceutics

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

(2019) Suzanne Trudel et al.   Blood Cancer Journal

The multiple myeloma drug market

(2019) Paul Wilcock et al.   NATURE REVIEWS DRUG DISCOVERY

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

(2019) Jie Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma

(2019) Margot J. Pont et al.   BLOOD

T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

(2018) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector

(2018) Eric L. Smith et al.   MOLECULAR THERAPY

APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications

(2018) Yu-Tzu Tai et al.   LEUKEMIA

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

(2018) Wan-Hong Zhao et al.   Journal of Hematology & Oncology

Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

(2018) Suzanne Trudel et al.   LANCET ONCOLOGY

Preclinical assessment of an antibody–PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells

(2018) Krista Kinneer et al.   LEUKEMIA

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

(2017) C S Chim et al.   LEUKEMIA

The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma

(2017) Eric Sanchez et al.   Targeted Oncology

Novel Immunotherapies for Multiple Myeloma

(2017) Mattia D’Agostino et al.   Current Hematologic Malignancy Reports

Multiple myeloma

(2017) Shaji K. Kumar et al.   Nature Reviews Disease Primers

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

(2016) S. A. Ali et al.   BLOOD

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment

(2016) Y.-T. Tai et al.   BLOOD

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo

(2016) S Hipp et al.   LEUKEMIA

Differential induction of plasma cells by isoforms of human TACI

(2015) Y. Garcia-Carmona et al.   BLOOD

Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities

(2015) G. Shay et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells

(2015) D Saulep-Easton et al.   LEUKEMIA

γ-secretase directly sheds the survival receptor BCMA from plasma cells

(2015) Sarah A. Laurent et al.   Nature Communications

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

(2014) Y.-T. Tai et al.   BLOOD

CVID-associated TACI mutations affect autoreactive B cell selection and activation

(2013) Neil Romberg et al.   JOURNAL OF CLINICAL INVESTIGATION

Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes

(2013) M Colombo et al.   LEUKEMIA

Deficiency in TNFRSF13B (TACI) expands T-follicular helper and germinal center B cells via increased ICOS-ligand expression but impairs plasma cell survival

(2012) X. Ou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas

(2011) M. Guadagnoli et al.   BLOOD

TACI deficiency impairs sustained Blimp-1 expression in B cells decreasing long-lived plasma cells in the bone marrow

(2011) S. Tsuji et al.   BLOOD

Transmembrane activator and CAML interactor (TACI) haploinsufficiency results in B-cell dysfunction in patients with Smith-Magenis syndrome

(2011) Javier Chinen et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The C104R mutant impairs the function of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) through haploinsufficiency

(2010) John J. Lee et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88

(2010) Bing He et al.   NATURE IMMUNOLOGY

Transmembrane activator, calcium modulator, and cyclophilin ligand interactor drives plasma cell differentiation in LPS-activated B cells

(2009) Esra Ozcan et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes

(2008) U. Salzer et al.   BLOOD